John I. Risinger

John I. Risinger

Auto-generated profile, based on publicly available information

John I. Risinger

Department of Obstetrics, Gynecology and Reproductive Biology, Michigan State University, 333 Bostwick Ave., NE, Grand Rapids, MI 49503, USA

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2003
Verified
Journal Article
Closed access
JRJohn I Risinger
John I Risinger
GMGeorge Larry Maxwell
George Larry Maxwell
GCG V R Chandramouli
G V R Chandramouli
AJAmir Jazaeri
Amir Jazaeri
OAOlga Aprelikova
Olga Aprelikova
JBJ Carl Barrett
J Carl Barrett

1 April 2015 in Biology of Reproduction
Verified
Journal Article
Open access
BHBrian L. Hood
Brian L. Hood
BLBaoquan Liu
Baoquan Liu
AAAddie Alkhas
Addie Alkhas
YSYutaka Shoji
Yutaka Shoji
RCRusheeswar Challa
Rusheeswar Challa
JRJohn I. Risinger
John I. Risinger
Despite its importance in reproductive biology and women's health, a detailed molecular-level understanding of the human endometrium is lacking. Inde

14 December 2017 in PLOS ONE
Verified
Journal Article
Open access
PDF file
HKHong Im Kim
Hong Im Kim
CSChad R Schultz
Chad R Schultz
ABAndrea L Buras
Andrea L Buras
EFElizabeth Friedman
Elizabeth Friedman
AFAlyssa Fedorko
Alyssa Fedorko
JRJohn I Risinger
John I Risinger
Ornithine Decarboxylase (ODC) a key enzyme in polyamine biosynthesis is often overexpressed in cancers and contributes to polyamine-induced cell proliferation. We noted ubiquitous expression of ODC1 in our published endometrial cancer gene array data and confirmed this in the cancer genome atlas (TCGA) with highest expression in non-endometrioid, high grade, and copy number high cancers, which have the worst clinical outcomes. ODC1 expression was associated with worse overall survival and increased recurrence in three endometrial cancer gene expression datasets. Importantly, we confirmed these findings using quantitative real-time polymerase chain reaction (qRT-PCR) in a validation cohort of 60 endometrial cancers and found that endometrial cancers with elevated ODC1 had significantly shorter recurrence-free intervals (KM log-rank p = 0.0312, Wald test p = 5.59e-05). Difluoromethylornithine (DFMO) a specific inhibitor of ODC significantly reduced cell proliferation, cell viability, and colony formation in cell line models derived from undifferentiated, endometrioid, serous, carcinosarcoma (mixed mesodermal tumor; MMT) and clear cell endometrial cancers. DFMO also significantly reduced human endometrial cancer ACI-98 tumor burden in mice compared to controls (p = 0.0023). ODC-regulated polyamines (putrescine [Put] and/or spermidine [Spd]) known activators of cell proliferation were strongly decreased in response to DFMO, in both tumor tissue ([Put] (p = 0.0006), [Spd] (p<0.0001)) and blood plasma ([Put] (p<0.0001), [Spd] (p = 0.0049)) of treated mice. Our study indicates that some endometrial cancers appear particularly sensitive to DFMO and that the polyamine pathway in endometrial cancers in general and specifically those most likely to suffer adverse clinical outcomes could be targeted for effective treatment, chemoprevention or chemoprevention of recurrence.

2 January 2020 in Cancers
Verified
Journal Article
Open access
PDF file
SKSuet Ying Kwan
Suet Ying Kwan
CYChi Lam Au Yeung
Chi Lam Au Yeung
TYTsz-Lun Yeung
Tsz-Lun Yeung
ARAngela Rynne-Vidal
Angela Rynne-Vidal
KWKwong-Kwok Wong
Kwong-Kwok Wong
KLKaren Lu
Karen Lu
Uterine serous carcinoma (USC) is the most aggressive form of endometrial cancer, with poor survival rates and high recurrence risk. Therefore, the purpose of this study was to identify therapeutic targets that could aid in the management of USC. By analyzing endometrial cancer samples from The Cancer Genome Atlas (TCGA), we found Ubiquitin Carboxyl-Terminal Hydrolase L1 (UCHL1) to be highly expressed in USC and to correlate with poorer overall survival. UCHL1 silencing reduced cell proliferation in vitro and in vivo, cyclin B1 protein levels and cell cycle progression. Further studies showed that UCHL1 interacts with cyclin B1 and increases cyclin B1 protein stability by deubiquitination. Treatment of USC-bearing mice with the UCHL1-specific inhibitor reduced tumor growth and improved overall survival. Our findings suggest that cyclin B1 is a novel target of UCHL1 and targeting UCHL1 is a potential therapeutic strategy for USC.

1 January 2013 in Frontiers in Oncology
Verified
Journal Article
Open access
PDF file
JRJohn I. Risinger
John I. Risinger
JAJay Allard
Jay Allard
UCUma Chandran
Uma Chandran
RDRoger Day
Roger Day
GCGadisetti V. R. Chandramouli
Gadisetti V. R. Chandramouli
GMGeorge Larry Maxwell
George Larry Maxwell
Endometrial cancer is the most common gynecologic malignancy in the United States but it remains poorly understood at the molecular level. This investigation was conducted to specifically assess whether gene expression changes underlie the clinical and pathologic factors traditionally used for determining treatment regimens in women with stage I endometrial cancer. These include the effect of tumor grade, depth of myometrial invasion and histotype. We utilized oligonucleotide microarrays to assess the transcript expression profile in epithelial glandular cells laser microdissected from 79 endometrioid and 12 serous stage I endometrial cancers with a heterogeneous distribution of grade and depth of myometrial invasion, along with 12 normal post-menopausal endometrial samples. Unsupervised multidimensional scaling analyses revealed that serous and endometrioid stage I cancers have similar transcript expression patterns when compared to normal controls where 900 transcripts were identified to be differentially expressed by at least fourfold (univariate t-test, p < 0.001) between the cancers and normal endometrium. This analysis also identified transcript expression differences between serous and endometrioid cancers and tumor grade, but no apparent differences were identified as a function of depth of myometrial invasion. Four genes were validated by quantitative PCR on an independent set of cancer and normal endometrium samples. These findings indicate that unique gene expression profiles are associated with histologic type and grade, but not myometrial invasion among early stage endometrial cancers. These data provide a comprehensive perspective on the molecular alterations associated with stage I endometrial cancer, particularly those subtypes that have the worst prognosis.

1 January 2012 in Frontiers in Oncology
Verified
Journal Article
Open access
PDF file
JAJay E. Allard
Jay E. Allard
GCGadisetti V. R. Chandramouli
Gadisetti V. R. Chandramouli
KSKatherine Stagliano
Katherine Stagliano
BHBrian L. Hood
Brian L. Hood
TLTracy Litzi
Tracy Litzi
JRJohn I. Risinger
John I. Risinger
Endometrial cancer is the most commonly diagnosed gynecologic malignancy in the United States. A well recognized disparity by race in both incidence and survival outcome exists for this cancer. Specifically Caucasians are about two times more likely to develop endometrial cancer than are African-Americans. However, African-American women are more likely to die from this disease than are Caucasians. The basis for this disparity remains unknown. Previous studies have identified differences in the types and frequencies of gene mutations among endometrial cancers from Caucasians and African-Americans suggesting that the tumors from these two groups might have differing underlying genetic defects. We performed a gene expression microarray study in an effort to identify differentially expressed transcripts between African-American and Caucasian women’s endometrial cancers. Our gene expression screen identified a list of potential biomarkers that are differentially expressed between these two groups of cancers. Of these we identified a poorly characterized transcript with a region of homology to phospho serine phosphatase (PSPH) and designated phospho serine phosphatase like (PSPHL) as the most differentially over-expressed gene in cancers from African-Americans. We further clarified the nature of expressed transcripts. Northern blot analysis confirmed the message was limited to a transcript of under 1 kB. Sequence analysis of transcripts confirmed two alternate open reading frame (ORF) isoforms due to alternative splicing events. Splice specific primer sets confirmed both isoforms were differentially expressed in tissues from Caucasians and African-Americans. We further examined the expression in other tissues from women to include normal endometrium, normal and malignant ovary. In all cases PSPHL expression was more often present in tissues from African-Americans than Caucasians. Our data confirm the African-American based expression of the PSPHL transcript in endometrial cancer and also identify its expression in other tissues from African-Americans including ovary and ovarian cancer. PSPHL represents a candidate gene that might influence the observed racial disparity in endometrial and other cancers.